Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Challenging welds – Your production, PEMA solution

Pemamek Oy hosts the second webinar of this year by introducing the PEMA robotic welding solutions for challenging welds and workpieces. As speakers, we have two experienced robotic welding professionals Teemu Rusi and Jyri Luhtio.We welcome you to join our webinar about PEMA solutions for challenging welds. How to make sure, that products with challenging welds are made efficiently and with the highest quality? In our second webinar of the year, we will take a deep dive into robotic welding. In the webinar, you will learn about our solutions for adaptive robotic welding and see how

myFC Lab Stories: From prestudy to delivery – myFC's project manager supervises the job

myFC Lab Stories is non-regulatory information from myFC's laboratory. The texts reflect the work that the company's researchers and developers carry out in the development of the patented technology. The numbers and data in this text are not to be considered as a forecast for future revenues. myFC has undergone a transformation – from the consumer market to being a technology supplier with a focus on B2B. The company is now taking active steps towards commercializing and mass production of their fuel cell technology LAMINA™ Strip to meet the needs of the ongoing electrification.– The

AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announced today that the company has signed an agreement with the consulting company TFS (TFS Trial Form Support AB) regarding pharmacovigilance which includes follow-up of side effects and safety regarding ISICORT®. The agreement is a regulatory milestone prior to the upcoming commercialization of ISICORT®.Under the terms of this agreement, AcuCort ensures that resources and processes are in place, and that the company meets the regulatory requirements regarding pharmacovigilance prior to the upcoming commercialization of the company's

Finnair's 2021 Annual Report has been published

Finnair Plc           Annual financial report           17 February 2022 at 10.00 a.m. EET Finnair Plc’s Report of the Board of Directors and Financial Statements 2021 were published today on 17 February 2022. The Report of the Board of Directors includes non-financial reporting.  Finnair publishes separately a Financial Information 2021 report, inclusive of Finnair Plc’s Report of the Board of Directors and Financial Statements, also in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format of the report is Extensible Hypertext Markup Language

BioStock: Chordate Medical’s CEO on UK market introduction

Chordate Medical recently began marketing introduction of its migraine treatment in the UK with the help of marketing consultants Futures.Health LTD. In addition, the list change to Nasdaq First North Growth Market is now completed. BioStock contacted Anders Weilandt for a comment.Read the full article at biostock.se: https://www.biostock.se/en/2022/02/chordate-medicals-ceo-on-uk-market-introduction/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

YEAR-END REPORT 2021

YEAR-END Report 2021 2022-02-17 - See attached pdf for full report -TOURN has had sales growth of 47% in 2021 and a historically high turnover during the fourth quarter. The Group reports a Q4 turnover of SEK 41 million which is a 32% increase from the previous highest level. Tourn chooses to raise SEK 50.6 million in directed issue during the period.Events Q4 2021 · Group shows sales growth of 47% 2021 resulting in a turnover of SEK 41 million · NAGATO grows by 130% compared to the same period 2020 · The company raises SEK 50.6 million in capital in a directed share

QUARTERLY REPORT, FOURTH QUARTER 2021

  Press release: Stockholm, February 17, 2022, 08.45 CET HIGHLIGHTS OF THE FOURTH QUARTER 2021 · Net sales was 99 MSEK compared to the previous year 78 MSEK. The positive contributor was favourable development of zinc price · EBITDA was 28 MSEK (7) · EBIT was 6 MSEK (-16) · Cash and cash equivalents were 37 MSEK (35) · Investments were 25 MSEK (14) including tailings pond dam raise amounting to 11 MSEK · The production was about 341 000 (349 000) ounces of silver, 869 (969) ounces of gold, 466 (330) tonnes of lead, and 1 049 (757) tonnes of zinc in

Gapwaves interim report October-December 2021: Increased sales and new customers

Gapwaves operations continue to develop positively and sales for the fourth quarter are about four times higher compared to the same period last year, which is a result of more customers and more development projects. Sales for the period October-December 2021 amounted to SEK 9.0 million (SEK 1.9 million).The most important events during the quarter and the greatest interest in Gapwaves technology are still within radar for the automotive industry. With Gapwaves unique waveguide technology, our antenna solves problems that the industry has struggled with for a long time. That Gapwaves

Trevian led the strategic development of Duetto Park – Business park sold to Revcap

The Duetto Park, managed by Trevian Asset Management in Helsinki, has been sold to Revcap Advisors Ltd (Revcap) after a development project. The purchase price is not disclosed. Trevian’s performance within the project has been an example of their strong strategic development work within the office space sector.British investor Revcap has acquired Duetto Park in Helsinki. The office property consists of two seven-storey interconnected buildings with a total of approximately 15,000 square meters of flexible office space.Trevian Asset Management has been responsible for the strategic

BioStock: Positive phase II results for Curasight in neuroendocrine cancer

Positive phase II study results keep on trickling in for Danish Curasight, strengthening its uPAR approach to diagnostics and cancer treatment. Latest in a string of news for the company when positive results regarding neuroendocrine cancer were announced and published in the Journal of Nuclear Medicine.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/positive-phase-ii-results-for-curasight-in-neuroendocrine-cancer/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Emory Healthcare expands enterprise imaging solution from Sectra with digital pathology

Linköping, Sweden and Shelton, CT – February 17, 2022 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed an agreement to add its digital pathology module to the Sectra enterprise imaging solution at Atlanta-based, Emory Healthcare. This will provide the pathologists with diagnostic quality viewing and analysis of pathology studies digitally, as well as enable integrated diagnostics.Emory Healthcare with nearly 24,000 employees and 11 hospital campuses, is the most comprehensive academic health system in Georgia and is part of

Bioservo Technologies AB Year-End Report 2021

Net sales increased by 13% for the fourth quarter 2021Fourth quarter in figures · Net sales of SEK 2.3 M (2.0) · EBITDA of SEK -7.5 M (-7.1) · EBIT of SEK -8.5 M (-8.1) · Earnings for the period amounted to SEK -8.5 M (-8.1) · Earnings per share before and after dilution amounted to SEK -0.45 (-0.55) · Cash flow from operating activities for the period amounted to SEK -8.5 M (-3.3) Year End in figures · Net sales of SEK 7.1M (11.7) · EBITDA of SEK -30.5 M (-22.3) · EBIT of SEK -34.7.2 M (-26.3) · Earnings for the period was SEK -34.7 M (-26.3) ·

K-Fast Holding AB (publ): Year-end report 2021

Financial ratios for the period 1 January–31 December 2021     +---------------------------------+----------+---------+---------+---------+|  Financial ratios |     2021 |    2020 |   2021 |   2020 || | Oct–Dec  |Oct–Dec  |Jan–Dec  | Jan–Dec |+---------------------------------+----------+---------+---------+---------+|  Rental income, SEK million |  75.3 |  56.2 |  265.9 | 203.9 |+---------------------------------+----------+---------+---------+---------+|  Profit from property |  27.0 |  19.1 |

XMReality AB (publ), Year-end report for 2021

On a full year basis the Net Sales totaled SEK 21,975 thousand representing a 6 percent increase, at the same time as the Order Backlog rose by 34 percent. The Annual Recurring Revenues (ARR) increased 6 percent during the year. The fourth quarter Net Sales was SEK 5,101 thousand, compared to SEK 7,072 thousand the corresponding quarter the previous year. Order Intake became SEK 25,964 thousand for the full year.The quarter October – December 2021 · Net sales amounted to SEK 5,101 thousand (7,072). · Cost totaled SEK -18,311 thousand (-14,482). · The operating loss before

Year-end report: Clear signs of favourable market trends after a challenging 2021

Significant   Other events in Q4events in Q4   · The · Enzymatica’s partner Sanofi received approval from theExtraordinary health authorities in Mexico (Cofepris) and Turkey (TITCK),General which enabled the launch of ColdZyme in these markets.Meeting on · In December, ColdZyme was approved as a “Natural HealthOctober 18, Product” by the Canadian authorities (Health Canada).2021, resolved · In December, the Patent Office in Mexico issued ato approve an preliminary ruling that it intends to grant

Immunovia Publishes Full Year Report 2021

LUND (SWEDEN) – Immunovia has today published its full year report 2021. It is available on Immunovia’s website. First product launched in US, well positioned for market penetration Fourth quarter · Net sales amounted to kSEK 305 (152) divided between sales of tests kSEK 278 (0) and royalties kSEK 27 (152). · Net earnings amounted to MSEK -47 (-46) and earnings per share before and after dilution were SEK -2.08 (-2.04). · Cash flow from operating activities amounted to MSEK -50 (-36). · Cash and cash equivalents at the end

Crunchfish publishes year-end report 2021

Today, Crunchfish AB (”Crunchfish”) publishes the company’s year-end report for 2021. Below is a brief summary of the report.Group financials 2021-10-01 2020-10-01 2021-01-01 2020-01-01 2021-12-31 2020-12-31 2021-12-31 2020-12-31         Net sales (SEK) 882,905 3,634,487 3,956,665 10,883,365Profit or loss -14,779,391 -5,880,294 -38,468,158 –25,335,425before tax (SEK)Earnings per -0.49 -0.21 -1.34 -0,91share (SEK)Equity-assets 87.0% 78.6%

Prevas presents its financial targets for the company

Prevas has developed steadily and strongly in recent years, and the final quarter of 2021 was marked by several records. Now is the time to clarify ambitions and financial goals going forward. Prevas’ management team and board of directors have thus reviewed and set the company's financial targets. The financial targets are:    · The EBITA margin shall amount to at least 10% over time. · Sales growth shall be qualitative and ultimately amount to at least 10% per year including acquisitions. · Net debt/EBITDA shall not exceed 2 over time. · Prevas’ dividend level

Jan Carlson proposed as new Board member of AB Volvo

Press information from AB Volvo’s Election CommitteeThe Election Committee of AB Volvo proposes that Jan Carlson be elected as new Board member at the Annual General Meeting on April 6, 2022. The Election Committee also proposes the re-election of the Chairman of the Board Carl-Henric Svanberg, as well as Board members Matti Alahuhta, Eric Elzvik, Martha Finn Brooks, Kurt Jofs, Martin Lundstedt, Kathryn V. Marinello, Martina Merz, Hanne de Mora and Helena Stjernholm. Eckhard Cordes will not stand for re-election.Jan Carlson, 61, is an experienced business leader in both corporate line

Arise AB (publ) has established a Green Financing Framework and investigates the possibility to issue green senior unsecured bonds

Arise AB (publ) (“Arise” or “the Company”), today announces its new Green Financing Framework (the “framework”). The framework outlines details for investments exclusively in renewable energy. Through these investments, Arise wishes to promote low carbon solutions and climate-resilient development. Please see the Green Financing Framework available on Arise’s website for further details, www.arise.se.   To confirm the framework’s alignment with the 2021 version of the ICMA Green Bond Principles, Arise has obtained a second-party opinion from Cicero Shades of Green. Cicero Shades of

Clinical study published regarding XNK Therapeutics’ NK cell-based product

XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital in Huddinge, Sweden, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma.“XNK is focused on the clinical development of autologous natural killer cell-based products

Citycon Board’s asset distribution proposal to the Annual General Meeting

CITYCON OYJ   Stock Exchange Release   17 February 2022 at 09:05 hrsThe Board of Directors of Citycon Oyj has decided to propose to the Annual General Meeting to be held on 22 March 2022 asset distribution as follows.The Board of Directors proposes that based on the balance sheet to be adopted for the financial period ended on 31 December 2021, no dividend is distributed by a resolution of the Annual General Meeting.Nonetheless, the Board of Directors proposes that the Board of Directors be authorized to decide in its discretion on the distribution of assets from the invested

Interim Q4 and Year-End 2021 Report

Continued Sportsook Growth in Q4; All Time High in Revenues in Year 2021Key Facts for the 4[th] Quarter 2021 (1[st] October 2021 – 31[th] December 2021) Continued growth in the Sportsbook All figures are compared to the same quarter last year if not explicitly stated otherwise · Revenues decreased by 19.03 % to €9,618,463 (€11,879,282). · EBIT decreased by 64.07% to €1,452,790 (€4,043,740). · EBIT margin of 15.10% (34.04%). · Customer deposits decreased by 18.90% to €20,507,189 (€25,286,513). · 64,604 new registered customers (71,767), decrease of 9.98%. · 15,551

There are no items matching the current filter
There are no more items matching the current filter
Back to top